Ophthalmology. Retina最新文献

{"title":"Understanding the Impact of Systemic Medications on Diabetic Retinal Disease","authors":"Paolo S. Silva MD","doi":"10.1016/j.oret.2025.03.006","DOIUrl":"10.1016/j.oret.2025.03.006","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"9 6","pages":"Pages 503-504"},"PeriodicalIF":4.4,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144196106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Characteristics and Treatment Outcomes in Unilateral Coats Disease","authors":"Andrew S.H. Tsai MBBS, FRCOphth ,&nbsp;Chung-Ting Wang MD ,&nbsp;Thomas C. Lee MD ,&nbsp;Aaron Nagiel MD, PhD ,&nbsp;Kate Matsunaga BA ,&nbsp;C. Armitage Harper III MD ,&nbsp;Edward H. Wood MD, FASRS ,&nbsp;Sang Jin Kim MD, PhD ,&nbsp;Sungsoon Hwang MD, PhD ,&nbsp;Michael J. Shapiro MD ,&nbsp;Michael P. Blair MD ,&nbsp;Cynthia A. Toth MD ,&nbsp;Nita Valikodath MD, MS ,&nbsp;Maria Ana Martinez-Castellanos MD ,&nbsp;Matthew G.J. Trese DO ,&nbsp;Antonio Capone Jr. MD ,&nbsp;Kimberly Drenser MD, PhD ,&nbsp;Zujaja Tauqeer MD, PhD ,&nbsp;Cagri G. Besirli MD, PhD ,&nbsp;Emily Eton MD ,&nbsp;Wei-Chi Wu MD, PhD","doi":"10.1016/j.oret.2024.11.017","DOIUrl":"10.1016/j.oret.2024.11.017","url":null,"abstract":"<div><h3>Purpose</h3><div>To evaluate the clinical outcomes and prognostic factors in unilateral Coats disease in the era of anti-VEGF therapy.</div></div><div><h3>Design</h3><div>Global, multicenter, retrospective case series.</div></div><div><h3>Subjects</h3><div>Six hundred fifty-six eyes of 656 subjects with Coats disease were included in this study. Exclusion criteria were Coats disease secondary to retinitis pigmentosa as well as bilateral cases.</div></div><div><h3>Methods</h3><div>Clinical data from patients with Coats disease were collected from 20 ophthalmic practices around the world. We compared early-stage (stage 1–2) and advanced-stage (stage 3–5) Coats disease in terms of clinical characteristics and treatment modalities.</div></div><div><h3>Main Outcome Measures</h3><div>Functional outcomes include achieving visual acuity (VA) of 0.3 logarithm of the minimum angle of resolution or better and VA improvement or stability. Anatomical failure was defined as the development of phthisis, chronic retinal detachment, massive fibrosis, or the requirement for enucleation.</div></div><div><h3>Results</h3><div>Subjects with early-stage disease were significantly older, with a mean age of 17.4 ± 17.8 years, compared with 7.1 ± 7.1 years in the advanced-stage group (<em>P</em> &lt; 0.001). There was a male predominance in both early and advanced stages (84.7%). Advanced disease was associated with a higher incidence of strabismus (20.2% vs. 6.7%, <em>P</em> &lt; 0.001) and leukocoria (12.3% vs. 3.2%, <em>P</em> &lt; 0.001). More subjects with early-stage disease received laser photocoagulation as monotherapy (44.7% vs. 21.1%, <em>P</em> &lt; 0.001). Additionally, early-stage disease received more sessions of intravitreal anti-VEGF injections as adjunct therapy (4.4 ± 6.2 vs. 2.7 ± 2.1, <em>P</em> = 0.005). Factors associated with poorer functional outcomes included worse presenting VA, advanced disease stage, and the presence of a foveal nodule. Worse presenting VA and advanced disease stage were associated with lower likelihood of anatomical success, whereas combination therapy increased the odds of anatomical success.</div></div><div><h3>Conclusions</h3><div>Unilateral Coats disease predominantly affects males, regardless of disease stage. Identifying a foveal nodule is crucial for visual prognosis. Laser photocoagulation remains the primary treatment. Although anti-VEGF may prevent enucleation, its role in early-stage disease requires further clarification.</div></div><div><h3>Financial Disclosure(s)</h3><div>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</div></div>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"9 6","pages":"Pages 570-579"},"PeriodicalIF":4.4,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142755360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Iris Coloboma and Iris Metastatic Tumor","authors":"Ryan Clarke,&nbsp;Adrian Au MD, PhD,&nbsp;Tara A. McCannel MD, PhD","doi":"10.1016/j.oret.2024.10.003","DOIUrl":"10.1016/j.oret.2024.10.003","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"9 6","pages":"Page e53"},"PeriodicalIF":4.4,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142583853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Novel Finding of Focal Scleral Defects in a Sclerochorioretinal Coloboma","authors":"Savithiri Palanivel DOMS, DNB,&nbsp;Anand Rajendran DNB, FRCS","doi":"10.1016/j.oret.2024.10.011","DOIUrl":"10.1016/j.oret.2024.10.011","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"9 6","pages":"Page e56"},"PeriodicalIF":4.4,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142625301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Subfoveal Choroidal Thickness in Patients with Histiocytosis and Multimodal Imaging Features of Choroidal Infiltrates","authors":"Jasmine H. Francis MD ,&nbsp;Anne S. Reiner MPH ,&nbsp;Julia Canestraro OD ,&nbsp;David H. Abramson MD ,&nbsp;Eli L. Diamond MD","doi":"10.1016/j.oret.2024.11.007","DOIUrl":"10.1016/j.oret.2024.11.007","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Purpose&lt;/h3&gt;&lt;div&gt;To evaluate choroidal findings in patients with histiocytosis, including subfoveal choroidal thickness (SFCT), and multimodal imaging in eyes with choroidal infiltrates visible by ophthalmoscopy and determine if abnormalities change with histiocytosis-directed (kinase inhibitor) therapy.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Design&lt;/h3&gt;&lt;div&gt;Retrospective comparative study at single tertiary cancer referral center.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Participants&lt;/h3&gt;&lt;div&gt;Ninety-one patients with histiocytosis and 41 age- and sex-matched controls.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;Clinical examination, fundus photography, and OCT were used to assess choroidal findings. Clinically evident choroidal infiltrates by ophthalmoscopy were recorded, and choroidal vascular architecture was qualitatively examined. Subfoveal choroidal thickness and was measured using enhanced depth imaging spectral domain OCT from the outer portion of Bruch membrane to the choroidal scleral interface.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Main Outcome Measures&lt;/h3&gt;&lt;div&gt;Subfoveal choroidal thickness was compared with matched controls; that secondary outcome was change in SFCT on histiocytosis-directed (kinase inhibitor) therapy. Multimodal imaging of choroidal infiltrates was visible by ophthalmoscopy.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;One hundred and eighty-two eyes of 91 patients (46 males, 45 females) with histiocytosis (Erdheim-Chester 35, Rosai-Dorfman 21, xanthogranuloma 7, mixed histiocytosis 11, Langerhans cell histiocytosis 15, and other 2) were examined. In patients with histiocytosis, the mean SFCT was 336.2 ± 94.9 μm compared with 250.3 ± 60.7 μm in the control group (&lt;em&gt;P&lt;/em&gt; &lt; 0.0001). Notably, 69% of patients with histiocytosis had SFCT &gt;275 μm compared with 27% in controls (&lt;em&gt;P&lt;/em&gt; &lt; 0.0001). Subtype of histiocytosis, sites of bone or central nervous disease, posterior segment/other sites of ophthalmic disease, or mutational profile did not correlate with SFCT. In a subgroup analysis of 35 patients naïve to prior treatment, with &gt;6 months follow-up, the proportion of SFCT &gt;275 μm significantly decreased (&lt;em&gt;P&lt;/em&gt; = 0.0016) on histiocytosis-directed (kinase inhibitor) therapy. Notably, 19.8% of patients had clinically evident choroidal infiltration: majority were yellow creamy, geographic, located posteriorly and hyperautofluorescent; with enlarged Haller vein bordering the infiltrate, choriocapillaris compression and loss of choroidal architecture by OCT.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusions&lt;/h3&gt;&lt;div&gt;In this cohort, 19.8% of patients with histiocytosis had clinically evident infiltration of their choroid. Furthermore, the majority of patients with histiocytosis had increased SFCT compared with age- and sex-matched controls. The thickened choroid decreases on histiocytosis-directed (kinase inhibitor) therapy and may be a marker of response to systemic treatment.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Financial Disclosure(s)&lt;/h3&gt;&lt;div&gt;Proprietary or commercial disclosure may be found ","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"9 6","pages":"Pages 580-588"},"PeriodicalIF":4.4,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142639460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Progressive Macular Excavation in RD3 Mutation","authors":"Srikanta Kumar Padhy MD","doi":"10.1016/j.oret.2024.10.022","DOIUrl":"10.1016/j.oret.2024.10.022","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"9 6","pages":"Page e60"},"PeriodicalIF":4.4,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142801936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Type 3 Macular Neovascularization in Age-related Macular Degeneration","authors":"Riccardo Sacconi MD, PhD ,&nbsp;Paolo Forte MD ,&nbsp;Giulia Corradetti MD ,&nbsp;Eliana Costanzo MD ,&nbsp;Vittorio Capuano MD ,&nbsp;Elodie Bousquet MD ,&nbsp;Federico Beretta MD ,&nbsp;Serena Iannuzzi MD ,&nbsp;Maria Sole Polito MD ,&nbsp;Massimo Nicolò MD ,&nbsp;Mariacristina Parravano MD ,&nbsp;Eric Souied MD, PhD ,&nbsp;David Sarraf MD ,&nbsp;SriniVas Sadda MD ,&nbsp;Francesco Bandello MD ,&nbsp;Giuseppe Querques MD, PhD","doi":"10.1016/j.oret.2024.11.011","DOIUrl":"10.1016/j.oret.2024.11.011","url":null,"abstract":"<div><h3>Purpose</h3><div>To identify baseline OCT predictors of the 3-year macular atrophy (MA) development for type 3 (T3) macular neovascularization (MNV) secondary to neovascular age-related macular degeneration (nAMD) treated by anti-VEGF therapy.</div></div><div><h3>Design</h3><div>Multicenter, retrospective, longitudinal study.</div></div><div><h3>Participants</h3><div>We included patients with treatment-naive T3 MNV secondary to nAMD at baseline, treated with anti-VEGF during a 3-year follow-up.</div></div><div><h3>Methods</h3><div>Patients were identified from 6 retinal referral institutions: (1) San Raffaele University, Milan, Italy; (2) University of Genova, Genova, Italy; (3) Doheny Eye Institute, Los Angeles; (4) Stein Eye Institute, Los Angeles; (5) University of Paris Est, Creteil, France; and (6) Istituto di Ricovero e Cura a Carattere Scientifico Bietti Foundation, Rome, Italy. Several baseline predictors of 3-year MA area were analyzed based on structural OCT and demographics.</div></div><div><h3>Main Outcome Measures</h3><div>Multivariate analysis to identify baseline independent predictors of the 3-year MA development for T3 MNV secondary to nAMD treated by anti-VEGF therapy.</div></div><div><h3>Results</h3><div>We included 131 eyes of 131 patients (mean age, 80 ± 6 years; 81% females). Best-corrected visual acuity was 0.49 ± 0.40 logarithm of the minimum angle of resolution (logMAR) at the baseline and significantly decreased to 0.59 ± 0.43 logMAR at the end of 3-year follow-up (<em>P</em> &lt; 0.001). Patients were treated with 11 ± 6 anti-VEGF injections and developed atrophy in 75% of cases (from 18% at the baseline). Eyes that developed 3-year MA were treated with a significantly lower number of injections compared with eyes without MA (9.9 ± 5.5 vs. 14.7 ± 7.2 injections, <em>P</em> &lt; 0.001). The most relevant independent predictors at baseline of MA area at 3-year follow-up were: area of MA at baseline (<em>P</em> &lt; 0.001), age-related macular degeneration phenotype (presence of reticular pseudodrusen) (<em>P</em> = 0.017), baseline presence of nascent geographic atrophy (<em>P</em> = 0.008), and the baseline presence of subretinal hyperreflective material (<em>P</em> = 0.002).</div></div><div><h3>Conclusions</h3><div>Macular atrophy development is a frequent complication of T3 MNV treated with anti-VEGF injections. Several factors could be considered baseline predictors of atrophy development during the anti-VEGF treatment.</div></div><div><h3>Financial Disclosure(s)</h3><div>The author(s) have no proprietary or commercial interest in any materials discussed in this article.</div></div>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"9 6","pages":"Pages 546-555"},"PeriodicalIF":4.4,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142682272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Insights into Cataract Surgery Outcomes in Age-Related Macular Degeneration","authors":"Leopold Hössl ,&nbsp;Shirin Ashraf Vaghefi MD ,&nbsp;Tommes Riemer MD ,&nbsp;Payam Kabiri MD ,&nbsp;Theresa Bonaventura MD ,&nbsp;Anne Rübsam MD ,&nbsp;Antonia M. Joussen MD ,&nbsp;Oliver Zeitz MD","doi":"10.1016/j.oret.2024.11.018","DOIUrl":"10.1016/j.oret.2024.11.018","url":null,"abstract":"<div><h3>Purpose</h3><div>Cataract and age-related macular degeneration (AMD) share age as a main risk factor and thus have a high coincidence. Both conditions substantially reduce visual acuity. This study aimed to assess the impact of cataract surgery on visual acuity, retinal morphology, and VEGF inhibitor therapy in patients with AMD.</div></div><div><h3>Design</h3><div>This study was designed as a retrospective, monocentric, real-world study.</div></div><div><h3>Subjects</h3><div>Patients diagnosed with either dry AMD or neovascular AMD undergoing cataract surgery at Charité Campus Benjamin Franklin.</div></div><div><h3>Methods</h3><div>Treatment data were extracted from the Berlin Macular Registry. Best-corrected visual acuity (BCVA) and macular OCT parameters, including central retinal thickness (CRT), macular volume (MV), presence of macular edema, intraretinal or subretinal fluid, and pigment epithelial detachment were assessed.</div></div><div><h3>Main Outcome Measures</h3><div>The primary outcome measure was the postoperative BCVA. Secondary outcomes included postoperative CRT, MV, changes in qualitative OCT parameters, alterations in anti-VEGF–therapy interval, and postoperative complications.</div></div><div><h3>Results</h3><div>A total of 418 eyes of 418 patients were included in the analysis with a mean follow-up time of 18.8 (2–62) months. They were classified into a neovascular AMD (n = 85) and a dry AMD (n = 333) cohort. Mean BCVA improved significantly in the neovascular AMD cohort from 0.69 ± 0.45 logarithm of the minimum angle of resolution (logMAR) to 0.47 ± 0.42 (<em>P</em> &lt; 0.001) and in the dry AMD cohort from 0.53 ± 0.47 logMAR to 0.27 ± 0.32 (<em>P</em> &lt; 0.001) at the 2-month follow-up. Improvements in BCVA were sustained to the final visit (18.8 ± 19.5 months after surgery) with BCVA at 0.46 ± 0.38 logMAR (<em>P</em> &lt; 0.001) and 0.26 ± 0.34 logMAR (<em>P</em> &lt; 0.001), respectively. Temporary postoperative increases in CRT and MV were observed, reverting to preoperative levels by 6 months after surgery. The need for anti-VEGF therapy did not change postoperatively in patients with neovascular AMD.</div></div><div><h3>Conclusions</h3><div>Within this retrospective analysis, on average, patients with coincident AMD of all severity grades meeting the inclusion criteria benefited from cataract surgery. Transient increases in retinal thickness and MV returned to baseline within 6 months after surgery. The need for intravitreal injections in neovascular AMD subjects was unchanged after surgery. Overall, the study suggests no adverse long-term macular changes attributable to cataract surgery.</div></div><div><h3>Financial Disclosure(s)</h3><div>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</div></div>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"9 6","pages":"Pages 527-536"},"PeriodicalIF":4.4,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142771129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Widefield Swept-Source OCT Angiography of Takayasu Retinopathy","authors":"Yanping Zhou MD ,&nbsp;Jinhui Dai MD, PhD ,&nbsp;Yongjin Zhang MD","doi":"10.1016/j.oret.2024.10.008","DOIUrl":"10.1016/j.oret.2024.10.008","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"9 6","pages":"Page e54"},"PeriodicalIF":4.4,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142625308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ocular Manifestations of Pallister-Killian Syndrome","authors":"Somya Kumari MD,&nbsp;Shivayan Srivastava MBBS,&nbsp;Shumaila Singh MBBS","doi":"10.1016/j.oret.2024.10.020","DOIUrl":"10.1016/j.oret.2024.10.020","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"9 6","pages":"Page e59"},"PeriodicalIF":4.4,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142710447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}